Live Breaking News & Updates on International Glaucoma

Stay updated with breaking news from International glaucoma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Glaukos Announces First Quarter 2024 Financial Results

Glaukos Corporation , an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced. ....

Thomas Burns , Corneal Health , Exchange Commission , Glaukos Corporation , International Glaucoma , Avedro Inc , Investor Relations , Quarterly Summary , Micro Invasive Glaucoma Surgery , Annual Report , Quarterly Report , Investor Section , Regarding Use , Generally Accepted Accounting Principles ,

Glaukos Announces Third Quarter 2023 Financial Results

ALISO VIEJO, Calif. (BUSINESS WIRE) Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the third quarter ended September 30, 2023. Key h. ....

Thomas Burns , Chris Lewis , Investor Relations Corporate Affairs , International Glaucoma , Exchange Commission , Glaukos Corporation , Avedro Inc , Corneal Health , Investor Relations , Quarterly Summary , Micro Invasive Glaucoma Surgery , Quarterly Report , Investor Section , Regarding Use , Generally Accepted Accounting Principles , Corporate Affairs ,

Glaukos Announces Second Quarter 2023 Financial Results

ALISO VIEJO, Calif. (BUSINESS WIRE) Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2023. Key highl. ....

Thomas Burns , Chris Lewis , Exchange Commission , Investor Relations Corporate Affairs , Corneal Health , Avedro Inc , Glaukos Corporation , International Glaucoma , Investor Relations , Quarterly Summary , Micro Invasive Glaucoma Surgery , Quarterly Report , Investor Section , Regarding Use , Generally Accepted Accounting Principles , Corporate Affairs ,

Glaukos Announces First Quarter 2023 Financial Results

ALISO VIEJO, Calif. (BUSINESS WIRE) Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2023. Key highl. ....

Thomas Burns , Chris Lewis , International Glaucoma , Investor Relations Corporate Affairs , Avedro Inc , Ivantis Inc , Exchange Commission , Corneal Health , Glaukos Corporation , Investor Relations , Quarterly Summary , Micro Invasive Glaucoma Surgery , Annual Report , Quarterly Report , Investor Section , Regarding Use , Generally Accepted Accounting Principles , Corporate Affairs ,

Glaukos Announces First Quarter 2023 Financial Results

Glaukos Corporation , an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced. | May 3, 2023 ....

Thomas Burns , International Glaucoma , Ivantis Inc , Corneal Health , Glaukos Corporation , Avedro Inc , Exchange Commission , Investor Relations , Quarterly Summary , Micro Invasive Glaucoma Surgery , Annual Report , Quarterly Report , Investor Section , Regarding Use , Generally Accepted Accounting Principles , Glaukos Corporation Stock Exchange , Press Release , Oday Gkos Us3773221029 ,